Leerink Partnrs Predicts Lower Earnings for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Analysts at Leerink Partnrs reduced their FY2027 EPS estimates for BridgeBio Pharma in a research note issued to investors on Sunday, November 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of $1.30 for the year, down from their previous forecast of $1.31. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.56) per share.

BBIO has been the topic of several other reports. Piper Sandler began coverage on shares of BridgeBio Pharma in a report on Wednesday, September 4th. They set an “overweight” rating and a $46.00 price target on the stock. Leerink Partners lowered their price target on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Bank of America upped their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $70.00 price target on shares of BridgeBio Pharma in a research note on Monday, September 16th. Finally, Scotiabank lifted their target price on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $48.43.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO opened at $26.44 on Tuesday. The company has a market cap of $5.00 billion, a P/E ratio of -10.97 and a beta of 1.09. The firm’s fifty day moving average is $24.97 and its two-hundred day moving average is $26.21. BridgeBio Pharma has a 52-week low of $21.62 and a 52-week high of $44.32.

Insiders Place Their Bets

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the transaction, the insider now owns 25,260,971 shares in the company, valued at $650,470,003.25. The trade was a 18.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Brian C. Stephenson sold 4,156 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the sale, the chief financial officer now owns 93,758 shares of the company’s stock, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,831,545 shares of company stock worth $150,056,923. 24.66% of the stock is owned by company insiders.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently modified their holdings of BBIO. Bfsg LLC raised its position in shares of BridgeBio Pharma by 175.6% during the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after acquiring an additional 790 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of BridgeBio Pharma in the second quarter valued at approximately $48,000. Values First Advisors Inc. acquired a new stake in shares of BridgeBio Pharma in the third quarter valued at approximately $57,000. CWM LLC raised its holdings in shares of BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after purchasing an additional 1,964 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its stake in shares of BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after buying an additional 1,645 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.